Hair Loss Treatments in Development: 2026 Pipeline Tracker
Published by AmpleLab Research
Statuses checked 9 October 2026
Search for new hair loss treatments and you tend to find two kinds of page: press releases announcing breakthroughs, and forum threads asking when they will arrive. What is usually missing is the middle: a plain map of what is being tested, how far along each candidate is, and what has been shown so far. This page is that map.
The two standard medicines for pattern hair loss, minoxidil and finasteride, date from the 1980s and 1990s. Over the past year several newer candidates have reported late-stage results. Most of the other names circulating online are far earlier, and a few have gone quiet.
We link every entry to our full article on it. Statuses come from company releases, trial registries and published papers, and they date quickly, so treat the date at the top as part of the content. Three of the entries, PTD-DBM, AHK-Cu and 2dDR, are actives in cosmetic serums that AmpleLab makes, and we say so where they appear.
The Short Version
Three candidates have reported positive late-stage results, and none was confirmed as approved for pattern hair loss in the sources we checked: clascoterone 5% (Breezula), pyrilutamide (KX-826) and extended-release oral minoxidil (VDPHL01). A fourth, sublingual minoxidil, has finished its Phase 3 trial but we found no published results. Most of the rest are in Phase 1 or earlier, and several have not reported for years.
How to Read a Pipeline
Drug development runs in stages. Preclinical work happens in cells and animals. Phase 1 tests safety in a small number of people, usually with little ability to show efficacy. Phase 2 looks for an early efficacy signal and a workable dose. Phase 3 repeats the test in a larger group and is what regulators expect before approval. After that comes a filing, a review and, if all goes well, a licence. A great deal falls away at each step, and a positive Phase 3 result is a milestone, not an approval.
Two further cautions apply throughout. A company topline release is a summary the company chose to write, while a peer-reviewed paper or trial registry record is slower and more detailed, so where we rely on a release we say so. And results from different trials cannot be lined up against each other: populations, strengths, durations and measurement methods all differ, which is why we link to the individual articles rather than ranking candidates here.
Status at a Glance
Closest to the Clinic: Late-Stage Results or Completed Trials
These four have the most data, and the most to prove. Two are topical androgen receptor blockers, designed to reduce androgen signalling at the follicle rather than inhibit DHT production systemically (our guide to the pathway is in DHT and the follicle). Two are new routes for minoxidil.
Clascoterone is the furthest along for scalp use. Its two Phase 3 trials, covering 1,465 men, reported six-month results in December 2025, and 12-month data followed in April 2026. Cosmo's July 2026 half-year results target a US filing in the first quarter of 2027 and a European filing in the second quarter. The headline figures are relative improvements over vehicle, which look large when the vehicle's own gain is small, and the full dataset is not yet published. Our Phase 3 article sets out the numbers, our absorption article tests the word "negligible", and the finasteride comparison claim is traced to its source.
The release reports target-area hair count improvements over vehicle of 539% in one trial and 168% in the other, both described as statistically significant (p<0.05), with adverse events similar to vehicle. It gives no exact p-values and no per-trial enrolment, and it is a company statement rather than a peer-reviewed paper.
Kintor reported in March 2026 that its China Phase 3 trial met the primary endpoint, with the 1.0% twice-daily strength adding 10.65 hairs/cm² over placebo and adverse events similar to placebo. Final analysis was shown at the World Congress for Hair Research in Seoul in late May, where the company said its marketing application was moving forward. We found no confirmed approval and no peer-reviewed publication of the Phase 3 data. Earlier US Phase 2 results were weaker, with the 0.5% strength missing statistical significance. Our KX-826 versus Breezula and KX-826 versus RU58841 articles cover how the evidence compares.
VDPHL01 is an extended-release oral minoxidil. Low-dose oral minoxidil is already prescribed off-label for hair loss, so the aim here is a licensed product with a different release profile. In the 519-man Study 302, reported in April 2026, hair counts at month 6 rose by 30.3 hairs/cm² (once daily) and 33.0 (twice daily) against 7.3 on placebo. Veradermics' August 2026 results put the confirmatory Phase 3 (Study 304) topline in the second half of 2026 and a 556-woman trial in the first half of 2027. Our comparison with oral minoxidil covers the safety side.
The release reports that 519 men were randomised to once-daily VDPHL01, twice-daily VDPHL01 or placebo, and that the trial met its primary and key secondary endpoints. Self-reported "improved" or "much improved" hair coverage was 48.4% and 62.9% on the two regimens against 13.4% on placebo, and adverse event rates were reported as similar to placebo. This is Part A of a larger study, reported by the company rather than in a journal.
Sublingual minoxidil is a tablet that dissolves under the tongue, tested as an alternative to swallowed oral minoxidil. The Phase 3 SAM-002 trial, a 24-week randomised placebo-controlled study, completed enrolment in November 2025. Samson's May 2026 announcement reported the last patient visit on 15 May and guided to topline results in the second quarter of 2026; its site gives a database lock date of 17 June. As of 9 October 2026 we found no published topline results.
Mid-Stage: Phase 1b to Phase 2/3
Mid-stage candidates have human efficacy data, usually from smaller trials, or are about to.
PP405 is a topical gel that inhibits the mitochondrial pyruvate carrier, a metabolic approach rather than a hormonal one. In its 78-patient Phase 2a, the company reported that 31% of patients on PP405 had a density increase of at least 20% at 8 weeks, against 0% on placebo. A $120 million Series B in October 2025 funded the next stage, and a registry listing now shows a randomised Phase 2/3 of 600 planned participants testing a 0.05% gel against vehicle for 24 weeks, with the vehicle group re-randomised to 52 weeks. It is listed as enrolling. For how it differs from our own ingredient, see PP405 and PTD-DBM compared.
GT20029 is a topical degrader designed to destroy the androgen receptor rather than block it. Its Phase 2 results, published in December 2025, were mixed: the 0.5% once-daily arm gained 16.80 hairs/cm² against 10.10 on placebo and the 1.0% twice-weekly arm 11.94 against 4.57, but only two of the four arms outperformed placebo. Kintor selected the 1.0% twice-weekly regimen for Phase 3, though we could not confirm that a pattern hair loss Phase 3 has begun.
OLX104C is an RNA interference drug that lowers the amount of androgen receptor protein the follicle makes, a third lever alongside reducing DHT and blocking its receptor. A Phase 1 safety study in 25 men reported no serious adverse events, and a Phase 1b/2a trial is registered. We found no published efficacy results.
ABS-201 is an antibody that blocks the prolactin receptor, which Absci is testing for pattern hair loss. Interim Phase 1 data in June 2026 suggested it was well tolerated with a half-life of at least 65 days. The company expects interim proof-of-concept data in the second half of 2026 and the full 26-week readout in early 2027, so there are no efficacy results yet.
The release describes ABS-201 as being in the Phase 1/2a HEADLINE trial, reports blinded aggregate interim data suggesting a favourable safety and tolerability profile, and estimates a half-life of at least 65 days from the four single-dose cohorts. It anticipates interim proof-of-concept data in the second half of 2026, and the full readout in early 2027. These are interim, blinded and company-reported.
Early Human Data
These candidates have only early human data, or have just announced a first hair study. Early safety trials are not designed to show that a treatment works, so the efficacy signals below are hypothesis-generating at best.
A 24-man Phase 1 reported that the 5% strength produced a sixfold greater increase in non-vellus hair count than placebo at week 5. That is a five-week result in a small group, so it is a signal to follow rather than evidence of benefit. The company discussed Phase 2 plans in early 2025, and we found no confirmation that Phase 2 has started.
AMP-303 grew out of research into why hair grows densely inside some moles. It has reached Phase 1, with 61 men in the trial we found, and no efficacy comparison against a standard treatment has been reported.
RLS-1496 aims to clear or modulate senescent cells, the ageing cells that accumulate in some tissues. Rubedo announced a hair clinical study in September 2026, and the evidence it has cited for hair so far is laboratory data on tissue taken from people, not trial results.
JW0061 is a topical Wnt pathway activator for which a Phase 1 trial has been announced and a US patent was granted in January 2026. Our article goes through the numbers behind the "7x minoxidil" claim attached to it.
Quiet, Unreported or Discontinued
Some candidates have not produced public data for a long time. That does not prove they failed, but it removes the basis for assuming they will arrive.
A 192-man Phase 2 trial of this prolactin receptor antibody is registered as completed, and we found no published results. It shares its target with ABS-201, so the first public efficacy data from either could say something about the whole approach.
In July 2024 the company reported a 12.3% hair count increase over vehicle (p = 0.008) in a Phase 1b/2a trial, against 9.8% in a 5% minoxidil arm. DLQ01 was not statistically compared with the minoxidil arm, the data have not appeared in a journal, and the company has not named the drug. As of mid-2026 it had not confirmed funding for the next phase.
This topical thyroid receptor beta agonist reported Phase 2a results in February 2024. The placebo group gained an unusually large amount of hair and the release gave no p-value, which makes the result hard to interpret. We found no later update.
Follicopeptide was discontinued by its maker. OND-1, a cyclosporine derivative, finished a Phase 1 trial in 2017 without any efficacy data being released, and its developer has since moved to an injectable formulation. Both are useful reminders of how many candidates stall.
Existing Compounds in New Roles
Not everything people ask about is a pipeline drug. These are existing compounds, approved for other things or sold as cosmetic ingredients, with their own evidence and their own caveats.
Approved for alopecia areata, an autoimmune condition. They are not approved for pattern hair loss, and the two are often confused online.
Topical finasteride and topical dutasteride
Reformulations of approved 5-alpha reductase inhibitors. The topical dutasteride evidence is still thin, and in our analysis of the 2025 trial, the numbers do not add up.
Several small trials exist, and it did worse than minoxidil when compared head to head. It is better thought of as a possible add-on than a replacement.
One randomised placebo-controlled trial of 40 women, using a 0.1% solution for six months, raised anagen rate over placebo. Most other studies are open-label.
It increases minoxidil absorption in an older study, and its standalone evidence is mixed.
Rapamycin and mTOR, NAD and fisetin and quercetin
Longevity-linked ideas where the evidence is limited or conflicting. Our articles cover where the studies disagree and where the claims run ahead of them.
BPC-157, verteporfin and the WNT5A-ATF3-FOSB pathway
Laboratory or informal-use territory, with no established clinical evidence for pattern hair loss. The pathway study describes biology, not a drug.
Cosmetic Actives With Early Research: PTD-DBM, AHK-Cu and 2dDR
Some of the ingredients people ask about are not drug candidates at all. They are cosmetic actives with early research behind them. Three are in AmpleLab's range, PTD-DBM, AHK-Cu and 2dDR: we make serums containing each of them, and we describe the evidence on the same terms as everything above.
A synthetic peptide from Kang-Yell Choi's laboratory at Yonsei University that blocks the interaction between CXXC5 and Dishevelled, a brake on Wnt/beta-catenin signalling in the follicle. A 2017 paper reported that a competing peptide of this kind stimulated hair regrowth and wound-induced follicle neogenesis in mice, and that CXXC5 is raised in human balding scalps. No human treatment trial has been published. Our guides to CXXC5 and the Wnt pathway cover the mechanism, and the AmpleLab PTD-DBM Hair & Scalp Serum page lists the formulation. For how the Wnt route differs from the metabolic approach in the pipeline, see the PP405 comparison.
A copper peptide studied for hair rather than skin. A 2007 study on human hair follicles kept in culture reported longer hair shaft elongation and signs of greater follicle cell proliferation. That is organ-culture work, which shows an effect on follicle cells in a dish rather than on a living scalp, and we found no published human trial of topical AHK-Cu. See also GHK-Cu versus AHK-Cu.
The sugar that forms the backbone of DNA, proposed to act by raising VEGF and supporting the blood supply around the follicle. The idea began in wound-healing research, and a 2024 study reported hair regrowth in a testosterone-induced alopecia mouse model. We found no published human trial for hair loss. Our 2dDR versus minoxidil article compares the evidence.
What to Watch Next
The next several months should answer some of the questions above. These are the readouts and filings we know are scheduled or guided, as stated by the companies concerned.
Until something is approved, nothing here changes what is available today. Approved options remain the baseline, and our pattern hair loss overview and protocol framework cover how to use them. For how much regrowth current evidence supports, see can hair loss be reversed. The investigational candidates and cosmetic formulations discussed here are not approved for pattern hair loss. Some existing medicines are approved for it, while others may be prescribed off-label. These are different regulatory situations.
Frequently Asked Questions
What new hair loss treatments are in development in 2026?
The furthest along are clascoterone 5% (Breezula), pyrilutamide (KX-826), extended-release oral minoxidil (VDPHL01) and sublingual minoxidil, all with Phase 3 data reported or trials completed. Behind them are PP405, GT20029, OLX104C and ABS-201 in Phase 1 to 2/3 trials, and a longer tail of early-stage or stalled candidates.
Which new hair loss treatment is closest to approval?
In the sources we checked, none is confirmed as approved for pattern hair loss yet. Cosmo is targeting a US filing for clascoterone in the first quarter of 2027, Kintor says its pyrilutamide marketing application is moving forward in China, and Veradermics expects a confirmatory Phase 3 readout for VDPHL01 in the second half of 2026.
Is there a cure for baldness in development?
No candidate we reviewed has shown human data consistent with a cure. Where absolute figures are reported, the placebo-adjusted gains in the late-stage trials are roughly 11 to 26 hairs per square centimetre (pyrilutamide and VDPHL01, from separate trials with different populations and methods), which is a measurable improvement rather than a restoration of lost density.
When will these treatments be available in the UK?
There is no reliable date yet. Even if a candidate succeeds in trials, it must still pass the relevant regulatory process, and approval in one country does not automatically mean approval in the UK. Cosmo has announced US and European filing targets for clascoterone in 2027, and Kintor is pursuing approval of pyrilutamide in China.
Where do PTD-DBM, AHK-Cu and 2dDR fit among these treatments?
They are cosmetic actives with early research, not drug candidates in clinical development. PTD-DBM and 2dDR have shown hair regrowth effects in mice, AHK-Cu stimulated human hair follicles in laboratory culture, and none has a published human treatment trial. AmpleLab makes serums containing each of them.
Can I buy these experimental hair loss drugs?
The investigational candidates in this article, such as clascoterone 5%, pyrilutamide and VDPHL01, are not approved treatments for pattern hair loss. Some existing medicines are approved for it, such as finasteride and minoxidil, and others, such as oral minoxidil, may be prescribed off-label by a clinician. Products sold online under the names of unapproved candidates are not trial material and carry no regulatory assurance about what they contain.
How often is this page updated?
Statuses were checked on 9 October 2026 and we revise the page when a trial reports, a filing is made or a programme is discontinued.
Selected Research
This article is provided for educational purposes and does not constitute medical advice. The investigational candidates and cosmetic formulations discussed are not approved for pattern hair loss. Some existing medicines are approved for it, while others may be prescribed off-label, and these are different regulatory situations. Trial statuses change and were checked on 9 October 2026. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition.
AmpleLab.